

- Bronchiolitis
 HMPV, 1206
 HRSV, 1205
 interstitial lung disease associated with, 1713
 parainfluenza virus, 1207
 Bronchiolitis obliterans, 320e-4, 372
 Bronchitis
 chronic, 244, 1692t, 1701. *See also* Chronic obstructive pulmonary disease (COPD)
 hemoptysis in, 245
 pathophysiology of, 306e-3
 Bronchoalveolar lavage
 in interstitial lung diseases, 1710, 1711t
 procedure, 1667
 in sarcoidosis, 2210, 2210f
 Bronchocentric granulomatosis, 1716
 Bronchodilators. *See* β -adrenergic agonists
 Bronchoscopy
 autofluorescence, 1667
 flexible fiberoptic, 1667
 in hypersensitivity pneumonitis, 1683
 in lung cancer diagnosis, 512
 in respiratory disease evaluation, 1663, 1667
 therapeutic, 1667
 virtual, 1666, 1666f
 Bronzing, in hemochromatosis, 2516
 Brown adipose tissue, 415e-2
 Brown recluse spider bite, 2747
 Brown-Séquard syndrome, 156, 161, 2652
 Brown tumor, 1815
Brucella spp., 194e-1, 194e-2
Brucella spp. infections, 194e-1
 chronic meningitis, 907t
 clinical features of, 152e-3t, 194e-2-3
 diagnosis of, 194e-3-4, 194e-3f
 epidemiology of, 194e-1
 global considerations in, 194e-1
 immune response to, 194e-1-2
 incubation period for, 152e-3t, 194e-2
 monocytosis in, 421
 osteomyelitis, 839
 pathogenesis of, 194e-1-2
 prevention of, 152e-3t, 194e-4-5
 prognosis of, 194e-4
 in returning war veterans, 152e-3t, 152e-8
 skin manifestations of, 366
 treatment of, 152e-3t, 194e-4
 vs. tuberculosis, 194e-2, 194e-2t
 Brudzinski's sign, 883
 Brugada's sign, 310
 Brugada syndrome
 clinical features of, 147, 1497
 ECG in, 273e-5, 1493f, 1497
 genetic considerations in, 147
 treatment of, 1497-1498
 ventricular arrhythmias in, 1495t
Brugia malayi, 245e-3t, 1417, 1418t. *See also* Lymphatic filariasis
Brugia timori, 1417, 1418t. *See also* Lymphatic filariasis
 Brunner's gland adenoma, 536
 Bruns-Garland syndrome, 2682-2683
 Brush border, 332e-6
 Bruxism, 192, 237
 Bryostatins, 102e-4f
 BSE (bovine spongiform encephalopathy), 453e-1t, 453e-2
 BTK gene, 2111
 B-type natriuretic peptide (BNP)
 in amyloidosis, 720
 in chest pain evaluation, 101
 in edema, 251
 in heart failure, 101, 287, 1505
 in pulmonary edema, 1763
 in pulmonary hypertension, 1657, 2161
 reference values for, 2758t
 in shock, 1746
 Bubble study, 1655
 Bubo, 261e-4, 829, 1072, 1072f
 Buccofacial apraxia, 179
 Bucindolol, 40
 Budd-Chiari syndrome (hepatic vein thrombosis)
 abdominal pain in, 106t
 ascites in, 287
 in hepatocellular carcinoma, 545, 2027
 liver transplantation for, 2068
 in paroxysmal nocturnal hemoglobinuria, 660
 in polycythemia, 399, 673
 recurrence of, after liver transplantation, 2074
 splenomegaly in, 411
 Budesonide, 270, 1960
 Buerger's disease (thromboangiitis obliterans), 1645-1646, 1649
 Bufadienolide, 310
 Buffalo hump, 1259, 1260f
 Buffalopox, 220e-1t, 220e-2
Bufo marinus (cane toad), 310
 Bufonidae spp., 473e-9t
 "Building-associated illness," 1663
 Bulbospinal pathway, 155f
 "Bulge sign," 2219
 Bulimia nervosa
 clinical features of, 2720
 hypokalemia in, 307
 nausea and vomiting in, 259
 oral manifestations of, 236
 treatment of, 2720
 Bullae. *See also* Vesicles/bullae
 characteristics of, 127, 827f
 description of, 339t, 340f
 etiology of, 828t, 829
 Bullet ant, 2749
 Bullous dermatosis of hemodialysis, 361t, 362
 Bullous impetigo, 349, 967. *See also* Impetigo
 Bullous pemphigoid. *See* Pemphigoid, bullous
 Bumetanide, 322, 1510t, 1763
 BUN. *See* Blood urea nitrogen (BUN)
 Bundobugo virus disease, 1325f, 1326f, 1327t
 Bundle branch reentry, 273e-4, 1495
 Bundle of His. *See* His bundle
 Bunyamwera virus, 1308t
 Bunyaviruses
 gene expression and replication in, 214e-4
 geographic distribution of, 1311t
 global considerations in, 782
 reservoirs and vectors of, 1305, 1306t
 structure of, 214e-2t, 214e-3f
 Bunyavirus infections. *See also* Hantavirus infections
 California meningoencephalitis, 1314
 clinical syndromes of, 1306t, 1312t, 1318
 Crimean-Congo hemorrhagic fever, 1321
 hemorrhagic fever with renal syndrome, 1321
 Orthobunyavirus group C serogroup, 1318
 Orthobunyavirus Simbu serogroup, 1318
 Rift valley fever. *See* Rift Valley fever
 sandfly fever, 152e-5t, 1318
 severe fever with thrombocytopenia syndrome, 1322
 Buprenorphine, 91t, 94, 468e-3-4
 Bupropion
 adverse effects of, 64, 507, 2710t, 2716
 for depression, 64, 2710t, 2716
 with naltrexone, for obesity, 2397
 for smoking cessation therapy, 507, 1705, 2732
 for SSRI-related sexual dysfunction, 2716
Burkholderia cepacia infections, 487, 1045t, 1048, 1697
Burkholderia mallei, 1049
Burkholderia pseudomallei, 152e-4t, 1045t, 1048
 Burkitt's lymphoma, 706
 clinical features of, 702t, 706
 diagnosis of, 81e-9f, 81e-11f, 706, 706f
 EBV infection and, 101e-7, 477t, 706
 endemic, 706
 genetic considerations in, 101e-3, 101e-3t, 698, 699t, 706
 in HIV infection, 706, 1270
 immunology of, 698, 698f
 malaria and, 1375
 oral manifestations of, 236
 during pregnancy, 124e-4
 sporadic, 706
 treatment of, 706
 tumor lysis syndrome in, 1795
 Burnett's syndrome, 2479
 Burning mouth syndrome (glossodynia; glossalgia), 215, 239
 Burnout syndrome, 475
 Burn patient
 acute kidney injury in, 1803
 complications in, 166e-1. *See also* Burn-wound infections
 hypocalcemia in, 315
 hypothermia in, 478e-1
 hypovolemia in, 298
 respiratory acidosis in, 323
 Burn-wound infections, 166e-1
 classification of, 166e-2
 clinical features of, 166e-1-2
 diagnosis of, 166e-2
 epidemiology of, 166e-1
 immunosuppression caused by, 166e-2
P. aeruginosa, 166e-1, 166e-2f, 1043
 pathophysiology of, 166e-1
 treatment of, 166e-3
 Burow's solution, 228
 Burrowing asps, 2733. *See also* Snakebites
 Bursitis, 2247
 Achilles, 2247
 anserine, 2222, 2248
 diagnosis of, 2247
 iliopsoas, 2247
 ischial, 2247
 olecranon, 2247
 pathophysiology of, 2247
 prepatellar, 2248
 retrocalcaneal, 2247
 subacromial, 2221, 2222
 treatment of, 2247
 trochanteric, 2222, 2222f, 2247
 Buschke-Ollendorff syndrome (dermatofibrosis lenticularis disseminata), 426e-5
 Buspirone
 for anxiety disorders, 2711, 2711t
 for cocaine abuse/dependence, 469e-2
 drug interactions of, 246e-3t
 for functional dyspepsia, 263
 for SSRI-related sexual dysfunction, 2716
 Busulfan
 adverse effects of, 694
 hepatic, 2025
 hyperpigmentation, 361, 379
 nausea and vomiting, 103e-25
 neurologic, 607
 pulmonary, 1797
 for CML, 694
 drug interactions of, 246e-3t
 genetic variations in response to, 39t
 in HSCT preparation, 139e-2
 Butabarbital, 473e-10t
 Butorphanol
 action of, 94
 for migraine, 2592t, 2593
 for pain, 91t, 92
 Butyrate, for stimulation of fetal hemoglobin, 639
 Bwamba virus, 1308t
 Byssinosis, 1688t, 1691
 Bystander killing, 1244
 C
 C1 inhibitor (C1INH) deficiency, 105, 372e-25t, 2118, 2119, 2120
 C1q, 372e-25t
 C3 glomerulopathy, 62e-4f
 C9ORF72 gene mutations, 2603
 Ca²⁺/calmodulin pathway, 1106
 CA 19-9, 473t, 553, 555
 CA-125
 in cholangiocarcinoma, 552
 in ovarian cancer, 482, 593
 reference values for, 2758t
 as tumor marker, 473t
 Cabazitaxel, 103e-15, 586
 Cabergoline, 565, 2267-2268, 2271
 CABG. *See* Coronary artery bypass grafting (CABG)